Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.
Sionna Therapeutics SION) stock rises as the clinical-stage biopharma focused on cystic fibrosis therapies makes its public ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...
The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
A study led by TUM researchers finds that cystic fibrosis alters immune cells early in life, likely before birth. These ...
The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...
Cystic fibrosis is a genetic disorder that changes a vital protein in the body, causing a buildup of thick and sticky mucus, ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback